U.S. flag An official website of the United States government.
Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

i

Evaluation of the Performance of the Cepheid Xpert HIV‐1 Viral Load Assay for Quantitative and Diagnostic Uses

Supporting Files
File Language:
English


Details

  • Alternative Title:
    J Clin Virol
  • Personal Author:
  • Description:
    Background

    Cepheid’s Xpert HIV‐1 Viral Load (Xpert VL), a simplified, automated, single-use quantitative assay used with the GeneXpert System, is not FDA-approved.

    Objectives

    Using stored plasma, we conducted a study to assess the ability of Xpert VL to quantify viral load relative to the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 (Cobas VL) and to examine the use of the Xpert VL as a qualitative diagnostic test.

    Study Design

    Following HIV-1 viral stock dilutions, we conducted a probit analysis to identify the concentration where 95% of specimens had quantified VLs. We also examined Xpert and Cobas log VL correlation in linearity panels; compared the proportion of 220 seroconverter specimens with virus detected using McNemar’s test; and tested specimens from persons with untreated, established HIV-1 infection (n=149) and uninfected persons (n=497). Furthermore, we examined Xpert VL as a qualitative test in seroconverter specimens with early (n=20) and later (n=68) acute infections.

    Results

    At 1.80 log10 copies/mL, 95% of specimens had quantifiable virus using Xpert VL. Xpert and Cobas VLs were highly correlated (R2=0.994). The proportion of seroconverter specimens with virus detected using Cobas and with Xpert VL was not statistically different (p=0.0578). Xpert VL detected 97.9% of established infections, and specificity was 99.80% (95% CI 98.87%−99.99%). Xpert VL detected 90% and 98.5% of early and later acute infections, respectively.

    Conclusions

    If approved, Xpert VL could allow U.S. laboratories that cannot bring on large, complex testing platforms to conduct HIV monitoring. An approval for diagnostic use may provide timely identification of HIV infections.

  • Subjects:
  • Keywords:
  • Source:
    J Clin Virol. 122:104214
  • Pubmed ID:
    31835210
  • Pubmed Central ID:
    PMC11089535
  • Document Type:
  • Funding:
  • Volume:
    122
  • Collection(s):
  • Main Document Checksum:
    urn:sha256:1e21c626bd6cd54e522e2e9a26d93d10cd9f094fa3b3fce5cb4f94d5d03044ce
  • Download URL:
  • File Type:
    Filetype[PDF - 739.42 KB ]
File Language:
English
ON THIS PAGE
 Was this page helpful?
 Found an issue?
Send us an email at:
CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.

As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.